Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled induction study of oral TAK-279 in moderately to severely active ulcerative colitis
CTR20253088Phase 2Active
- Sponsor
- Takeda
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zasocitinib in autoimmune colitis, sponsored by Takeda. Started Oct 2025; status: active.
02
Drugs
zasocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20253088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253088.